AbbVie Signs Two Option and License Agreements with Umoja Biopharma to Develop CAR-T Cell Therapies for Hematologic Malignancies
Shots:
- As per the 1st agreement, AbbVie receives an exclusive option to license Umoja's CD19 directed in-situ generated CAR-T cell therapy candidates incl. UB-VV111 for hematologic malignancies (in IND-enabling phase)
- As per the 2nd agreement, AbbVie & Umoja will jointly develop up to four additional in-situ generated CAR-T cell therapy candidates for targets selected by AbbVie by using Umoja’s VivoVec gene delivery platform
- Under the terms of both agreements, Umoja will receive an up front payment along with equity investments & is eligible to receive an aggregate of up to $1.44B for option exercise fees, development & regulatory milestones with the potential to earn additional sales-based milestones plus tiered royalties
Ref: AbbVie | Image: AbbVie
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
